Hereditary Breast And Ovarian Cancer Syndrome Jeopardy Template

Pathophysiology	Screening	Risk Reduction Options
100 Tumor supressors The BRCA genes encodes for these type of proteins?	100 What is 1 in 300, to 1 in 800 Represents the incidence of BRCA 1 and 2 mutations in the general population	100 What is Bilateral BSO Prophylactic risk reducing option for ovarian cancer, and should be offered to individuals with BRCA mutations by age 40 or following desire for future fertility
200 Two Hit Hypothesis This hypothesis describes the development of cancer in individuals with known mutation	200 What is 39-46%, and 12-20% Represents the risk of ovarian cancer in individuals with known BRCA 1 and 2 mutations respectively	200 What is tamoxifen This chemopreventive therapy has been found to be useful in reducing risks of breast cancer in patients with BRCA 2 mutaions
300 Serous or Endometriod type, High Grade This histologic type of ovarian cancer has been most strongly associated with BRCA mutations	300 What is -Women with personal history of breast or ovarian cancer -Women with ovarian cancer and a close relative with ovarian cancer, or premenopausal breast cancer -Women with ovarian cancer who are of Ashkenazi jewish ancestry -Women with breast cancer The following risk factors warrant genetic screening for BRCA mutations	300 What is surveillance, chemoprevention, risk reducing surgery The three different options pts should be offered when diagnosed with known BRCA mutation
400 What is periodic CA 125, TVUS at age 30-35, or 5-10yrs before incident case and semiannual clinical breast exam, along with annual mammography or breast MRI at age 25 or earlier based on family history Represent the recommended screening modalities for individuals with BRCA mutations

Hereditary Breast and Ovarian Cancer Syndrome

Press F11 for full screen mode